Raremark appoints Caroline O’Connor as CCO

pharmafile | February 4, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Raremark has appointed Caroline O’Connor as its new Chief Commercial Officer.

Previously holding the position of Raremark’s Senior Vice President of Business Development, O’Connor will now take ownership of the company’s commercial focus and play a key role in growing its presence in the pharma industry.

Prior to joining the company, O’Connor’s focus was on eClinical technology, combined with establishing value and driving revenue growth from real-world evidence and digital patient support programmes in the post-approval setting.

Jeremy Edwards, Raremark’s CEO, said: “I’m thrilled to name Caroline as our Chief Commercial Officer. Since joining the organisation, her depth of industry knowledge and experience in motivating teams has made a significant impact. I’m confident she will lead us into the next exciting phase of our growth journey.

“This year we will reach even more patients, make an even bigger impact on their lives, and make further strides in rare disease research and development, and Caroline’s abilities will be instrumental in taking us there.”

Related Content

No items found

Latest content